Treatment of follicular lymphoma: Current status

Leukemia and Lymphoma

Volumn 49, Issue SUPPL. 1, 2008, Pages 7-17

  Tilly, Hervé ^a   Zelenetz, Andrew ^b  

^a CENTRE HENRI BECQUEREL   (France)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

First line treatment; Follicular lymphoma; Non Hodgkin lymphoma; Rituximab; Second line treatment

Indexed keywords

ALPHA INTERFERON; BENDAMUSTINE; BORTEZOMIB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; FLUDARABINE; GALIXIMAB; IBRITUMOMAB TIUXETAN; INTERFERON; MITOXANTRONE; PREDNIMUSTINE; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE; VINDESINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SCREENING; FOLLICULAR LYMPHOMA; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RISK ASSESSMENT; SINGLE DRUG DOSE; SURVIVAL RATE; TREATMENT RESPONSE; WATCHFUL WAITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, FOLLICULAR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 53349097826     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802311391     Document Type: Article

References (72)

1. The Non-Hodgkin's Lymphoma Classification Project (1997) A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. Blood, 89, pp. 3909-3918.
2. Johnson, P. W., Rohatiner, A. Z., Whelan, J. S., Price, C. G., Love, S. Lim, J. et al. (1995) Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center. J Clin Oncol, 13, pp. 140-147.
3. Montoto, S., Davies, A. J., Matthews, J., Calaminici, M., Norton, A. J. Amess, J. et al. (2007) Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol, 25, pp. 2426-2433.
4. Horning, S. J. and Rosenberg, S. A. (1984) The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med, 311, pp. 1471-1475.
5. O'Brien, M. E., Easterbrook, P., Powell, J., Blackledge, G. R., Jones, L. MacLennan, I. C. et al. (1991) The natural history of low grade non-Hodgkin's lymphoma and the impact of a no initial treatment policy on survival. Q J Med, 80, pp. 651-660.
6. Portlock, C. S. and Rosenberg, S. A. (1979) No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types. Ann Intern Med, 90, pp. 10-13.
7. Ardeshna, K. M., Smith, P., Norton, A., Hancock, B. W., Hoskin, P. J. MacLennan, K. A. et al. (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial. Lancet, 362, pp. 516-522.
8. Brice, P., Bastion, Y., Lepage, E., Brousse, N., Haioun, C. Moreau, P. et al. (1997) Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the groupe d'etude des lymphomes folliculaires. Groupe d'etude des lymphomes de l'adulte. J Clin Oncol, 15, pp. 1110-1117.
9. Young, R. C., Longo, D. L., Glatstein, E., Ihde, D. C., Jaffe, E. S. and DeVita Jr, V. T. (1988) The treatment of indolent lymphomas: Watchful waiting v aggressive combined modality treatment. Semin Hematol, 25, pp. 11-16.
10. Swenson, W. T., Wooldridge, J. E., Lynch, C. F., Forman-Hoffman, V. L., Chrischilles, E. and Link, B. K. (2005) Improved survival of follicular lymphoma patients in the United States. J Clin Oncol, 23, pp. 5019-5026.
11. McLaughlin, P., Grillo-Lopez, A. J., Link, B. K., Levy, R., Czuczman, M. S. Williams, M. E. et al. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol, 16, pp. 2825-2833.
12. Ghielmini, M., Schmitz, S. F., Cogliatti, S. B., Pichert, G., Hummerjohann, J. Waltzer, U. et al. (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood, 103, pp. 4416-4123.
13. Foran, J. M., Gupta, R. K., Cunningham, D., Popescu, R. A., Goldstone, A. H. Sweetenham, J. W. et al. (2000) A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol, 109, pp. 81-88.
14. Igarashi, T., Kobayashi, Y., Ogura, M., Kinoshita, T., Ohtsu, T. Sasaki, Y. et al. (2002) Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: A Japanese phase II study. Ann Oncol, 13, pp. 928-943.
15. Colombat, P., Salles, G., Brousse, N., Eftekhari, P., Soubeyran, P. Delwail, V. et al. (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood, 97, pp. 101-106.
16. Hainsworth, J. D., Litchy, S., Burris HA, I II, Scullin Jr, D. C., Corso, S. W. Yardley, D. A. et al. (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol, 20, pp. 4261-4267.
17. Davis, T. A., White, C. A., Grillo-Lopez, A. J., Velasquez, W. S., Link, B. Maloney, D. G. et al. (1999) Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab. J Clin Oncol, 17, pp. 1851-1857.
18. Davis, T. A., Grillo-Lopez, A. J., White, C. A., McLaughlin, P., Czuczman, M. S. Link, B. K. et al. (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol, 18, pp. 3135-3143.
19. Czuczman, M. S., Weaver, R., Alkuzweny, B., Berlfein, J. and Grillo-Lopez, A. J. (2004) Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol, 22, pp. 4711-4716.
20. Overman, M. J., Feng, L., Pro, B., McLaughlin, P., Hess, M. Samaniego, F. et al. (2007) The addition of rituximab to CHOP chemotherapy improves response rate, failure-free survival and overall survival for follicular grade 3 lymphoma compared to CHOP alone. Blood, 110, p. 1289.
21. Hainsworth, J. D., Litchy, S., Morrissey, L. H., Andrews, M. B., Grimaldi, M. McCarty, M. et al. (2005) Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: A phase II trial of the minnie pearl cancer research network. J Clin Oncol, 23, pp. 1500-1506.
22. Economopoulos, T., Fountzilas, G., Pavlidis, N., Kalantzis, D., Papageorgiou, E. Christodoulou, C. et al. (2003) Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma. Hematol J, 4, pp. 110-115.
23. Savage, D. G., Cohen, N. S., Hesdorffer, C. S., Heitjan, D., Oster, M. W. Garrett, T. J. et al. (2003) Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia. Leuk Lymphoma, 44, pp. 477-481.
24. Sacchi, S., Pozzi, S., Marcheselli, R., Federico, M., Tucci, A. Merli, F. et al. (2007) Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. Cancer, 110, pp. 121-128.
25. Zinzani, P. L., Pulsoni, A., Perrotti, A., Soverini, S., Zaja, F. De Renzo, A. et al. (2004) Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol, 22, pp. 2654-2661.
26. Forstpointner, R., Dreyling, M., Repp, R., Hermann, S., Hanel, A. Metzner, B. et al. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German low-grade lymphoma study group. Blood, 104, pp. 3064-3071.
27. Martinelli, G., Laszlo, D., Bertolini, F., Pastano, R., Mancuso, P. Calleri, A. et al. (2003) Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. Br J Haematol, 123, pp. 271-277.
28. Rummel, M. J., Atta, J., Welslau, M., Kofahl-Krause, D., von Gruenhagen, U. Schalk, K. et al. (2007) Bendamustine and rituximab (BR) are effective in the treatment of relapsed or refractory indolent and mantle-cell lymphomas: Long-term follow-up of a phase II study. J Clin Oncol, 25, p. 8034.
29. Suzuki, Y., Danbara, M., Hayama, M., Togano, T., Ohsaka, M. Miyazaki, K. et al. (2007) Phase II: Combination of cladribine, cyclophosphamide, mitoxantrone, rituximab (R-CCM) in patients with relapsed and refractory follicular and mantle cell lymphoma, results of a prospective study at Kitasato University. J Clin Oncol, 25, p. 18542.
30. Schulz, H., Bohlius, J. F., Trelle, S., Skoetz, N., Reiser, M. Kober, T. et al. (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis. J Natl Cancer Inst, 99, pp. 706-714.
31. Forstpointner, R., Unterhalt, M., Dreyling, M., Bock, H. P., Repp, R. Wandt, H. et al. (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood, 108, pp. 4003-4008.
32. van Oers, M. H., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E. Gascoyne, R. D. et al. (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood, 108, pp. 3295-3301.
33. Cheung, M. C., Berinstein, N. L., Pennell, N., Hicks, L. K., Imrie, K. R. Piliotis, E. et al. (2007) Prolonged clinical and molecular remissions following high-dose therapy/autologous stem cell transplantation (HDT/ASCT) and rituximab and interferon-alpha maintenance for relapsed high-risk follicular lymphoma. Blood, 110, p. 1902.
34. Ladetto, M., De Marco, F., Benedetti, F., Vitolo, U., Patti, C. Rambaldi, A. et al. (2007) Long-term follow-up of the randomized GITMO/ IIL trial comparing CHOP-rituximab vs. high-dose therapy rituximab (R-HDS) in high risk follicular lymphoma (FL): Updated results suggest the use of R-HDS as salvage treatment. Blood, 110, p. 20.
35. Friedberg, J. W., Huang, J., Dillon, H., Farber, C., Feliciano, S. Hainsworth, J. et al. (2006) Initial therapeutic strategy in follicular lymphoma (FL): An analysis from the National lymphocare study (NLCS). J Clin Oncol, 24, p. 7527.
36. Solal-Celigny, P., Roy, P., Colombat, P., White, J., Armitage, J. O. Arranz-Saez, R. et al. (2004) Follicular lymphoma international prognostic index. Blood, 104, pp. 1258-1265.
37. Sebban, C., Mounier, N., Brousse, N., Belanger, C., Brice, P. Haioun, C. et al. (2006) Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the groupe d'etude des lymphomes de l'adulte (GELA). Blood, 108, pp. 2540-2544.
38. Foussard, C., Mounier, N., Van Hoof, A., Delwail, V., Casasnovas, O. Deconinck, E. et al. (2006) Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts). J Clin Oncol, 24, p. 7508.
39. Primary Rituximab and Maintenance Study ClinicalTrials. gov Identifier: NCT0014058-[cited 2008 May 07].
40. Witzig, T. E., Vukov, A. M., Habermann, T. M., Geyer, S., Kurtin, P. J. Friedenberg, W. R. et al. (2005) Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: A phase II trial in the North Central cancer treatment group. J Clin Oncol, 23, pp. 1103-1108.
41. Hainsworth, J. D., Litchy, S., Shaffer, D. W., Lackey, V. L., Grimaldi, M. and Greco, F. A. (2005) Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - a randomized phase II trial of the Minnie Pearl cancer research network. J Clin Oncol, 23, pp. 1088-1095.
42. Kahl, B. S. (2006) Eastern cooperative oncology group 4402: Rituximab extended schedule or retreatment trial (RESORT). Clin Lymphoma Myeloma, 6, pp. 423-426.
43. Ghielmini, M. (2005) Multimodality therapies and optimal schedule of antibodies: Rituximab in lymphoma as an example. Hematol Am Soc Hematol Educ Program, 2005, pp. 321-328.
44. Zelenetz, A. D., Abramson, J. S., Advani, R. H., Byrd, J. C., Czuczman, M. S. Damon, L. E. et al. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphoma V3. 2007-[cited 2008 May 12].
45. Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E. Catalano, J. et al. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, pp. 1417-1423.
46. Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E. Schmits, R. et al. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German low-grade lymphoma study group. Blood, 106, pp. 3725-3732.
47. Herold, M., Haas, A., Srock, S., Neser, S., Al-Ali, K. H. Neubauer, A. et al. (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German study group hematology and oncology study. J Clin Oncol, 25, pp. 1986-1992.
48. Marcus, R., Solal-Celigny, P., Imrie, K., Catalano, J. V., Dmoszynska, A. Raposo, J. C. et al. (2006) MabThera (Rituximab) plus cyclophosphamide, vincristine and prednisone (CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkin's lymphoma (NHL). Blood, 108, p. 481.
49. Salles, G. A., Mounier, N., de Guibert, S., Morschhauser, F., Doyen, C. Rossi, J-F et al. (2007) Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Final analysis of the GELA-GOELAMS FL2000 study with a 5-year follow-up. Blood, 110, p. 792.
50. Federico, M., Bellei, M., Pro, B., Lopez-Guillermo, A., Marcheselli, L. Trneny, M. et al. (2007) Revalidation of FLIPI in patients with follicular lymphoma (FL) registered in the F2 study and treated upfront with immunochemotherapy. J Clin Oncol, 25, p. 8008.
51. Press, O. W., Unger, J. M., Braziel, R. M., Maloney, D. G., Miller, T. P. Leblanc, M. et al. (2006) Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol, 24, pp. 4143-4149.
52. Hagenbeek, A., Bischof-Delaloye, A., Radford, J. A., Rohatiner, A., Salles, G. Van Hoof, Achiel et al. (2007) 90Y-Ibritumomab Tiuxetan (Zevalin®) consolidation of first remission in advanced stage follicular non-Hodgkin's lymphoma: First results of the international randomized phase 3 first-line indolent trial (FIT) in 414 Patients. Blood, 110, p. 643.
53. Bischof-Delaloye, A., Antonescu, C. and Hagenbeek, A. (2007) Dosimetric analysis of 90Y-Ibritumomab tiuxetan (Zevalin®) given as consolidation of first remission in patients with advanced-stage follicular lymphoma in the international phase 3 First-Line Indolent Trial (FIT). Blood, 110, p. 3415.
54. Gondek, K., Shah, S., Bischof-Delaloye, A., Rohatiner, A., Salles, G. Put, Barbara et al. (2007) Health-related quality of life in patients with advanced-stage follicular lymphoma receiving consolidation with 90Y-ibritumomab tiuxetan (Zevalin®) of first remission: Results from the randomized phase 3 First-Line Indolent Trial (FIT). Blood, 110, p. 3319.
55. Hochster, H. S., Weller, E., Ryan, T., Habermann, T. M., Gascoyne, R. Frankel, R. et al. (2004) Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). J Clin Oncol, 22, p. 6502.
56. Ladetto, M., De Marco, F., Benedetti, F., Vitolo, U., Patti, C. Passera, R. et al. (2007) Prospective, multicenter, randomized GITMO-IIL trial comparing intensive (R-HDS) to conventional chemoimmunotherapy (CHOP-R) in high-risk follicular lymphoma (FL) at diagnosis. J Clin Oncol, 25, p. 8006.
57. Vose, J. M., Wahl, R. L., Saleh, M., Rohatiner, A. Z., Knox, S. J. Radford, J. A. et al. (2000) Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol, 18, pp. 1316-1323.
58. Zelenetz, A. D., Saleh, M., Vose, J. M., Younes, A. and Kaminski, M. S. (2002) Patients with transformed low grade lymphoma attain durable responses following outpatient radioimmunotherapy with tositumomab and Iodine I131 tositumomab (Bexxar). Blood, 100, p. 1384.
59. Horning, S. J., Younes, A., Jain, V., Kroll, S., Lucas, J. Podoloff, D. et al. (2005) Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol, 23, pp. 712-719.
60. Witzig, T. E., White, C. A., Wiseman, G. A., Gordon, L. I., Emmanouilides, C. Raubitschek, A. et al. (1999) Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol, 17, pp. 3793-3803.
61. Bartlett, N. L., Witzig, T. E., Gordon, L., Beck, T., Fehrenbacher, L. Kornmehl, E. et al. (2002) 90Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B-cell non-Hodgkin's lymphoma (NHL) patients. Proc Am Soc Clin Oncol, 21, p. 51.
62. Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C. Joyce, R. et al. (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol, 20, pp. 2453-2463.
63. Witzig, T. E., Flinn, I. W., Gordon, L. I., Emmanouilides, C., Czuczman, M. S. Saleh, M. N. et al. (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol, 20, pp. 3262-3269.
64. Wiseman, G. A., Gordon, L. I., Multani, P. S., Witzig, T. E., Spies, S. Bartlett, N. L. et al. (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood, 99, pp. 4336-4342.
65. Fisher, R. I., Kaminski, M. S., Wahl, R. L., Knox, S. J., Zelenetz, A. D. Vose, J. M. et al. (2005) Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol, 23, pp. 7565-7573.
66. Witzig, T. E., Molina, A., Gordon, L. I., Emmanouilides, C., Schilder, R. J. Flinn, I. W. et al. (2007) Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer, 109, pp. 1804-1810.
67. Schouten, H. C., Qian, W., Kvaloy, S., Porcellini, A., Hagberg, H. Johnson, H. E. et al. (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol, 21, pp. 3918-3927.
68. Vose, J., Bierman, P., Lynch, J., Bociek, G. and Armitage, J. (2005) Long-term outcomes of autologous stem cell transplantation for follicular non-hodgkin's lymphoma: Effect of histologic grade. J Clin Oncol, 23, p. 6567.
69. O'Connor, O. A., Wright, J., Moskowitz, C., Straus, D., Portlock, C. Hamlin, P. et al. (2005) Targeting the proteasome pathway with bortezomib in patients with mantle cell (MCL) and follicular lymphoma (FL) produces prolonged progression free survival among responding patients: Results of a multicenter phase II experience. Ann Oncol, 16, p. 99.
70. de Vos, S., Dakhil, S., McLaughlin, P., Saleh, M., Belt, R. Flowers, C. et al. (2005) Bortezomib plus rituximab in patients with indolent non-hodgkin's lymphoma (NHL): A phase 2 study. Blood, 106, p. 17.
71. Czuczman, M. S., Thall, A., Witzig, T. E., Vose, J. M., Younes, A. Emmanouilides, C. et al. (2005) Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol, 23, pp. 4390-4398.
72. Strauss, S. J., Morschhauser, F., Rech, J., Repp, R., Solal-Celigny, P. Zinzani, P. L. et al. (2006) Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol, 24, pp. 3880-3886.